Showing results (51-60 of 101) with videos related to
Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|September 8, 2009
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patientsEnric Carcereny, Jose Luis Ramirez, Maria Sanchez-Ronco, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2018
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung CancerNiki Karachaliou, Jillian Wilhelmina Paulina Bracht, Manuel Fernandez Bruno, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2014
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancerMiguel A Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, et al.Translational Lung Cancer Research|September 27, 2019
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)Mariano Provencio, Enric Carcereny, Delvys Rodríguez-Abreu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialCarlota Costa, Miguel Angel Molina, Ana Drozdowskyj, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialRoss A Soo, Urania Dafni, Ji-Youn Han, et al.European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic riskVirginia Calvo, Emetis Niazmand, Enric Carcereny, et al.Pageof 11